

**SCHOTT Pharma AG & Co. KGaA  
Mainz**

ISIN: DE000A3ENQ51 - WKN: A3ENQ5

**Announcement of dividend and appropriation of profits**

The ordinary Annual General Meeting of SCHOTT Pharma AG & Co. KGaA resolved on 14 March 2024, in accordance with the resolution proposed by the general partner and the Supervisory Board, to distribute a partial amount of EUR 22,592,192.40 from the company's net retained earnings of EUR 50,052,476.32 from the past fiscal year 2022/2023 to pay a dividend of EUR 0.15 for each of the 150,614,616 shares entitled to dividends for the fiscal year 2022/2023 and to carry forward the remaining amount of EUR 27,460,283.92 to new account. In accordance with Section 58 para. 4 sentence 2 of the German Stock Corporation Act, the dividend entitlement is due on the third business day following the Annual General Meeting resolution, i.e. on 19 March 2024.

The dividend is generally paid by the custodian banks via Clearstream Banking AG, Frankfurt am Main, after a deduction of 25% for capital gains tax and a 5.5% solidarity surcharge on the capital gains tax (i.e. a total of 26.375%) and, when applicable, a church tax on the capital gains tax. The central paying agent is COMMERZBANK Aktiengesellschaft, Frankfurt am Main.

Capital gains tax and the solidarity surcharge will not be deducted for shareholders with unlimited tax liability who have submitted a "non-assessment certificate" from their competent tax office to their custodian bank. The same applies in whole or in part to shareholders who have submitted an "exemption order" to their custodian bank, provided that the exemption volume stated in this order has not already been exhausted by other income from capital assets.

In the case of shareholders with limited tax liability, the withheld capital gains tax including the solidarity surcharge may be reduced in accordance with any existing double taxation agreements between the Federal Republic of Germany and the country concerned. Any refund will be made by the Federal Central Tax Office upon application.

Mainz, March 2024

**SCHOTT Pharma AG & Co. KGaA**  
***The General Partner***  
**SCHOTT Pharma Management AG**  
***The Management Board***